Article
Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
European journal of haematology - 1 May 2020
Calleja Anne, Yun Seongseok, Moreilhon Chimène, Karsenti Jean Michel, Gastaud Lauris, Mannone Lionel, Komrokji Rami, Al Ali Najla, Dadone-Montaudie Bérangère, Robert Guillaume, Auberger Patrick, Raynaud Sophie, Sallman David A, Cluzeau Thomas
Abstract excerpt
INTRODUCTION: Therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML) are defined as complications of previous cytotoxic therapy. Azacitidine (AZA), a hypomethylating agent, has showed activity in t-MDS/AML. OBJECTIVES: We evaluated the clonal dynamics of AZA-treated t-MDS/AML. METHODS: We collected bone marrow samples, at diagnosis and during treatment, from AZA-treated t-MDS/AML...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.